Lupin is currently trading at Rs. 1892.80, up by 17.10 points or 0.91% from its previous closing of Rs. 1875.70 on the BSE.
The scrip opened at Rs. 1875.00 and has touched a high and low of Rs. 1904.90 and Rs. 1875.00 respectively. So far 8953 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2112.00 on 08-Apr-2015 and a 52 week low of Rs. 1012.20 on 10-Jul-2014.
Last one week high and low of the scrip stood at Rs. 1928.05 and Rs. 1843.90 respectively. The current market cap of the company is Rs. 85275.67 crore.
The promoters holding in the company stood at 46.59% while Institutions and Non-Institutions held 43.57% and 9.84% respectively.
Foreign institutional investors (FIIs) have raised their stake in Lupin by 206 basis points to 36.75 percent at the end of June 2015 from 34.69 percent as on March 31, 2015. On the other hand, domestic institutional investors (DIIs) have decreased their stake in the company by 185 basis points to 6.82 percent at the end of June 2015 from 8.67 percent as on March 31, 2015.
Non Institutions were holding 9.84 percent stake at the end of June 2015, down 17 basis points from 10.01 percent as on March 31, 2015, while corporate bodies were holding 1.1 percent stake at the end of June 2015, down 4 basis points from 1.14 percent as on March 31, 2015.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: